文献速递心境障碍焦虑、强迫与应激相关障碍

抑郁焦虑应用临床试验的 uptake、依从性与脱落:系统综述与meta分析

Uptake, Adherence, and Attrition in Clinical Trials of Depression and Anxiety Apps: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

提供提醒、人际接触及无游戏化特征的试验脱落率更低。

要点

  • 应用初始使用率92.4%,依从率61.8%,治疗后脱落率18.6%,随访脱落率28.4%。
  • 提供提醒、人际接触和无游戏化特征的试验脱落率更低。
  • 应用组脱落风险高于等待名单组(风险比1.49),与其他对照无显著差异。

核心结论

  • 该meta分析为未来试验规划提供了应用使用率、依从性和脱落的基准值,并提示可修改的设计特征可能提升用户参与度。

研究设计与样本

  • 检索来源包括2024年综述(检索至2024年1月)及Medline和PsycINFO的更新检索(2024年1月至2025年5月),采用Cochrane偏倚风险评估工具,使用多水平随机效应模型进行meta分析。

主要发现

  • 应用初始使用率的meta分析值为92.4%(95%预测区间48.4%-99.4%),来自56个条件。
  • 应用依从率的meta分析值为61.8%(95%预测区间53.2%-69.7%),来自21个条件。
  • 治疗后脱落率的meta分析值为18.6%(95%预测区间2.4%-68.3%),随访脱落率为28.4%(95%预测区间3.0%-83.7%)。
  • 提供提醒、人际接触和无游戏化特征的试验脱落率更低。
  • 应用组脱落风险高于等待名单组(风险比1.49;95%预测区间0.34-6.48),与其他对照无显著差异。

关键数值与推荐

  • 应用初始使用率92.4%(95%预测区间48.4%-99.4%),来自56个条件。
  • 应用依从率61.8%(95%预测区间53.2%-69.7%),来自21个条件。
  • 治疗后脱落率18.6%(95%预测区间2.4%-68.3%),随访脱落率28.4%(95%预测区间3.0%-83.7%)。
  • 应用组与等待名单组脱落风险比1.49(95%预测区间0.34-6.48)。

临床怎么用

  • 可将上述使用率、依从率和脱落率作为抑郁焦虑应用临床试验设计与样本量估算的参考基准。
  • 在应用设计中考虑加入提醒和人际接触、避免游戏化特征,可能有助于降低脱落率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Randomized clinical trials (RCTs) support apps as scalable, cost-efficient tools for managing depression and anxiety, but concerns about engagement and attrition remain. With the field's rapid growth, there is now an opportunity to generate more precise insights on uptake, attrition, and adherence. OBJECTIVE: To examine patterns of uptake (initial activation of the app), adherence (use meeting the trial's definition of adequate engagement), and attrition (failure to complete outcome assessments) from RCTs of mental health apps for depression and anxiety. DATA SOURCES: Studies were identified from a 2024 review of RCTs on depression and anxiety apps (search through January 2024), with an updated search in Medline and PsycINFO conducted from January 2024 to May 2025. STUDY SELECTION: Trials of mental health apps delivered to participants with depression or anxiety were eligible if they reported rates of uptake, adherence, or attrition. DATA EXTRACTION AND SYNTHESIS: Study characteristics were extracted by 2 independent reviewers. The Cochrane Risk of Bias tool was used. Meta-analyses were conducted using multilevel random-effects models. MAIN OUTCOMES AND MEASURES: Meta-analyses were conducted on app uptake, posttest and follow-up attrition, and adherence. Absolute rates were estimated using pooled event rates, while relative rates (apps vs controls on attrition) were calculated using pooled risk ratios. RESULTS: Seventy-nine trials, including 92 app conditions and 78 control conditions, were included (k = 39 for depression, k = 26 for anxiety, and k = 14 for transdiagnostic samples). The meta-analytic rate of app uptake was 92.4% (95% prediction interval [PI], 48.4%-99.4%) from 56 conditions. The meta-analytic rate of app adherence was 61.8% (95% PI, 53.2%-69.7%) from 21 conditions. The meta-analytic posttest attrition rate was 18.6% (95% PI, 2.4%-68.3%), and at follow-up, it was 28.4% (95% PI, 3.0%-83.7%). Attrition rates were lower among trials that offered reminders, human contact, and no gamification features. Attrition was higher in app conditions than wait-lists (risk ratio, 1.49; 95% PI, 0.34-6.48) but did not differ significantly to other controls. CONCLUSIONS AND RELEVANCE: The findings of this meta-analysis offer benchmarks for future trial planning while highlighting modifiable design features that may enhance user engagement.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Liu C, Torous J, Fuller-Tyszkiewicz M, et al. Uptake, Adherence, and Attrition in Clinical Trials of Depression and Anxiety Apps: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2026. PMID: 41259035. doi:10.1001/jamapsychiatry.2025.3439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。